What Britannia Pharmaceuticals does

Britannia Pharmaceuticals is a UK-based, privately held specialty pharmaceutical company headquartered in London, founded in 1981. According to its self-description, it focuses on innovative products for chronic and serious medical conditions, with an explicit therapeutic emphasis on the treatment of Parkinson's disease. The firm operates with a headcount of 51-100 employees, placing it in the small-to-mid-sized specialty pharma segment, and maintains a corporate web presence at britannia-pharm.co.uk.

The company's portfolio is positioned around differentiated therapeutics for serious and chronic indications — most prominently Parkinson's disease, a therapeutic area that typically relies on specialty/reimbursed distribution channels and regulator-approved formulations. No specific product names, formulations, mechanisms of action, or pipeline assets are enumerated in the available source data, and no technology platform, patents, or proprietary drug-delivery systems are described. Likewise, no certifications, regulatory filings, geographic operating footprint, or clinical milestones are documented in the supplied material.

The revenue model is not directly disclosed: there is no pricing data, no product-level revenue split, no customer segmentation, and no channel or partnership information in the input. As a pharmaceutical firm in a regulated, reimbursed category, the implied mechanics are product sales to healthcare providers, payers, and specialty distributors, but the absence of any financial disclosure — combined with a website scrape that returned only a verification/loading screen rather than substantive content — materially limits the depth of any business-model characterization.

Name

Britannia Pharmaceuticals

Website

https://britannia-pharm.co.uk

Company type

Private

Founded year

1981

Operating status

Operating

Headcount range

51–100 employees

Short description

Britannia Pharmaceuticals is a London-based, privately held specialty pharmaceutical company founded in 1981 that develops innovative treatments for chronic and serious medical conditions, with a particular focus on Parkinson's disease.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Parkinson's disease treatment
• Neurology pharmaceuticals
• Chronic disease therapy
• Specialty pharmaceuticals
• Movement disorder drugs

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Core offering

Britannia Pharmaceuticals develops and supplies pharmaceutical products focused on the treatment of Parkinson's disease and other chronic and serious medical conditions. The company operates as a specialty pharmaceutical manufacturer based in London, UK, producing therapeutics for neurological and chronic indications.

Differentiator

Problem solved

Functional benefit

Products and services

• Parkinson's disease therapeutics
• Chronic disease therapeutics

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Direct peers

• Lundbeck: Danish specialty pharmaceutical company focused on CNS/neurology. Highly comparable as a CNS-focused specialty pharma with Parkinson's-adjacent assets and a similar boutique-scale European operating model.
• Orion Corporation: Finnish specialty pharma with proprietary Parkinson's treatments (e.g., entacapone-based products). Comparable as a smaller European specialty pharma with Parkinson's as a core franchise.
• Acorda Therapeutics: US specialty pharma historically centered on Parkinson's disease therapeutics (e.g., Inbrija). Comparable as a smaller specialty pharma with concentrated Parkinson's focus.
• Amneal Pharmaceuticals: Specialty and generics manufacturer with a meaningful Parkinson's franchise (e.g., generic apomorphine and carbidopa/levodopa products). Comparable as a Parkinson's-focused specialty/generics competitor targeting the same prescriber base.

Broad incumbents

• AbbVie: Global biopharmaceutical company with a deep CNS/Parkinson's franchise (e.g., Duopa/Vyalev via apomorphine delivery). Comparable as a major incumbent actively competing in advanced Parkinson's therapeutics.
• UCB: Belgian biopharmaceutical company with a strong CNS specialty portfolio and global commercial reach. Comparable as a European-headquartered specialty pharma with neurology focus.
• Teva Pharmaceutical Industries: Global generics and specialty pharma with Parkinson's products including generic apomorphine. Comparable as a broad incumbent offering both specialty and generic Parkinson's therapeutics.
• Stada Arzneimittel: European specialty and generics pharmaceutical company with Parkinson's-related products in its portfolio. Comparable as a Europe-focused specialty/generics player with overlapping CNS offerings.

Regional players

• Mitsubishi Tanabe Pharma: Japanese pharmaceutical company with established Parkinson's treatments and CNS franchise. Comparable as a regional specialty pharma operating a Parkinson's portfolio, primarily in Asia.
• Kyowa Kirin: Japanese specialty pharma with neurology/CNS products including Parkinson's-adjacent assets. Comparable as a regional specialty pharma with overlapping CNS indications.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Britannia Pharmaceuticals